Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis
- 1Department of Thoracic Surgery, The First People’s Hospital of Jiande
- 2Department of Gynecology, The First People’s Hospital of Jiande
Abstract
Background: Prolonged overall treatment time (OTT) during definitive radiotherapy has long been considered detrimental in cervical cancer, but the magnitude and consistency of its prognostic association across treatment eras remain uncertain. We evaluated the association between OTT and oncologic outcomes after definitive radiotherapy or chemoradiotherapy.
Methods: PubMed/MEDLINE, Embase, Web of Science Core Collection, Scopus, and the Cochrane Library were searched from inception through August 1, 2026. Eligible studies assessed OTT from initiation of external-beam radiotherapy through completion of the planned definitive radiotherapy course as either a categorical or continuous prognostic factor. Risk of bias was assessed using the Quality In Prognosis Studies tool. Time-to-event estimates were pooled as hazard ratios (HRs) with 95% confidence intervals (CIs) using random-effects models.
Results: Nineteen studies comprising 15,859 patients were included. Ten independent cohorts contributed to the primary overall survival (OS) analysis. Prolonged OTT was associated with poorer OS (HR, 1.61; 95% CI, 1.30–1.99; I² = 76%). In the prespecified analysis of three independent cohorts comparing OTT >56 versus ≤56 days, the association persisted (HR, 1.16; 95% CI, 1.04–1.31; I² = 37%). Prolonged OTT was also associated with a higher risk of local/pelvic/in-field failure (HR, 1.80; 95% CI, 1.26–2.56; I² = 46%). The OS association was consistent across treatment-era and cutoff-source subgroups and remained robust in sensitivity analyses.
Conclusion: Prolonged OTT is associated with poorer survival and a higher risk of local/pelvic/in-field failure after definitive radiotherapy or chemoradiotherapy for cervical cancer. These findings support timely completion of definitive radiotherapy and indicate that the 56-day interval remains a clinically relevant benchmark.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261470588 , identifier CRD420261470588.
Related
- A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?
- Multimodal Large Language Models for Prognostic Prediction in Cervical Cancer Treated with Definitive Chemoradiotherapy: An Exploratory Study of Systematic Multimodal Data Integration.
- Safety of neoadjuvant radiotherapy or chemoradiotherapy combined with immunotherapy across solid tumors: Systematic review and meta-analysis protocol
- Salvage gastrectomy for perforated gastric intramural metastasis after definitive chemoradiotherapy for distal esophageal squamous cell carcinoma: a case report.
- InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.
BibTeX
@article{ruan2026overall,
title = {{Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis}},
author = {Yingding Ruan and Yun Li and Dan Wu and Jianwei Han and Jianxia Cheng},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1969525},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1969525/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis
AU - Yingding Ruan
AU - Yun Li
AU - Dan Wu
AU - Jianwei Han
AU - Jianxia Cheng
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1969525
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1969525/full
AB - Background: Prolonged overall treatment time (OTT) during definitive radiotherapy has long been considered detrimental in cervical cancer, but the magnitude and consistency of its prognostic association across treatment eras remain uncertain. We evaluated the association between OTT and oncologic outcomes after definitive radiotherapy or chemoradiotherapy. Methods: PubMed/MEDLINE, Embase, Web of Science Core Collection, Scopus, and the Cochrane Library were searched from inception through August 1, 2026. Eligible studies assessed OTT from initiation of external-beam radiotherapy through completion of the planned definitive radiotherapy course as either a categorical or continuous prognostic factor. Risk of bias was assessed using the Quality In Prognosis Studies tool. Time-to-event estimates were pooled as hazard ratios (HRs) with 95% confidence intervals (CIs) using random-effects models. Results: Nineteen studies comprising 15,859 patients were included. Ten independent cohorts contributed to the primary overall survival (OS) analysis. Prolonged OTT was associated with poorer OS (HR, 1.61; 95% CI, 1.30–1.99; I² = 76%). In the prespecified analysis of three independent cohorts comparing OTT >56 versus ≤56 days, the association persisted (HR, 1.16; 95% CI, 1.04–1.31; I² = 37%). Prolonged OTT was also associated with a higher risk of local/pelvic/in-field failure (HR, 1.80; 95% CI, 1.26–2.56; I² = 46%). The OS association was consistent across treatment-era and cutoff-source subgroups and remained robust in sensitivity analyses. Conclusion: Prolonged OTT is associated with poorer survival and a higher risk of local/pelvic/in-field failure after definitive radiotherapy or chemoradiotherapy for cervical cancer. These findings support timely completion of definitive radiotherapy and indicate that the 56-day interval remains a clinically relevant benchmark. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261470588 , identifier CRD420261470588.
SN - 2234-943X
ER -